341 related articles for article (PubMed ID: 28451802)
21. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
22. The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party.
Iacobucci I; Lonetti A; Paoloni F; Papayannidis C; Ferrari A; Storlazzi CT; Vignetti M; Cilloni D; Messa F; Guadagnuolo V; Paolini S; Elia L; Messina M; Vitale A; Meloni G; Soverini S; Pane F; Baccarani M; Foà R; Martinelli G
Haematologica; 2010 Oct; 95(10):1683-90. PubMed ID: 20534699
[TBL] [Abstract][Full Text] [Related]
23. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Yeh CH; Abdool A; Bruey JM
Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia.
Yao QM; Liu KY; Gale RP; Jiang B; Liu YR; Jiang Q; Jiang H; Zhang XH; Zhang MJ; Chen SS; Huang XJ; Xu LP; Ruan GR
BMC Cancer; 2016 Apr; 16():269. PubMed ID: 27067989
[TBL] [Abstract][Full Text] [Related]
25. Mutational analysis in BCR-ABL1 positive leukemia by deep sequencing based on nanopore MinION technology.
Minervini CF; Cumbo C; Orsini P; Anelli L; Zagaria A; Impera L; Coccaro N; Brunetti C; Minervini A; Casieri P; Tota G; Russo Rossi A; Specchia G; Albano F
Exp Mol Pathol; 2017 Aug; 103(1):33-37. PubMed ID: 28663031
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
Roberts KG; Pei D; Campana D; Payne-Turner D; Li Y; Cheng C; Sandlund JT; Jeha S; Easton J; Becksfort J; Zhang J; Coustan-Smith E; Raimondi SC; Leung WH; Relling MV; Evans WE; Downing JR; Mullighan CG; Pui CH
J Clin Oncol; 2014 Sep; 32(27):3012-20. PubMed ID: 25049327
[TBL] [Abstract][Full Text] [Related]
27. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
[TBL] [Abstract][Full Text] [Related]
28. High frequency of BTG1 deletions in patients with BCR-ABL1-positive acute leukemia.
Xie J; Wang Q; Wang Q; Yao H; Wen L; Ma L; Wu D; Chen S
Cancer Genet; 2014 May; 207(5):226-30. PubMed ID: 24998463
[TBL] [Abstract][Full Text] [Related]
29. Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response.
Iacobucci I; Lonetti A; Venturi C; Ferrari A; Papayannidis C; Ottaviani E; Abbenante MC; Paolini S; Bresciani P; Potenza L; Parisi S; Cattina F; Soverini S; Russo D; Luppi M; Martinelli G
Leuk Res; 2014 May; 38(5):581-5. PubMed ID: 24630366
[TBL] [Abstract][Full Text] [Related]
30. Detection of BCR-ABL1 mutations that confer tyrosine kinase inhibitor resistance using massively parallel, next generation sequencing.
Szankasi P; Schumacher JA; Kelley TW
Ann Hematol; 2016 Jan; 95(2):201-10. PubMed ID: 26555285
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
Pfeifer H; Lange T; Wystub S; Wassmann B; Maier J; Binckebanck A; Giagounidis A; Stelljes M; Schmalzing M; Dührsen U; Wunderle L; Serve H; Brück P; Schmidt A; Hoelzer D; Ottmann OG
Leukemia; 2012 Jul; 26(7):1475-81. PubMed ID: 22230800
[TBL] [Abstract][Full Text] [Related]
32. Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
Short NJ; Jabbour E; Macaron W; Ravandi F; Jain N; Kanagal-Shamanna R; Patel KP; Loghavi S; Haddad FG; Yilmaz M; Issa GC; Kebriaei P; Kornblau SM; Pelletier S; Flores W; Matthews J; Garris R; Kantarjian H
Am J Hematol; 2023 Aug; 98(8):1196-1203. PubMed ID: 37183966
[TBL] [Abstract][Full Text] [Related]
33. Adult acute lymphoblastic leukemia with a rare b3a3 type BCR/ABL1 fusion transcript.
Kurita D; Hatta Y; Hojo A; Kura Y; Sawada U; Kanda Y; Takei M
Cancer Genet; 2016 Apr; 209(4):161-5. PubMed ID: 26854094
[TBL] [Abstract][Full Text] [Related]
34. CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients.
Iacobucci I; Ferrari A; Lonetti A; Papayannidis C; Paoloni F; Trino S; Storlazzi CT; Ottaviani E; Cattina F; Impera L; Abbenante MC; Vignetti M; Vitale A; Potenza L; Paolini S; Soverini S; Pane F; Luppi M; Foà R; Baccarani M; Martinelli G
Clin Cancer Res; 2011 Dec; 17(23):7413-23. PubMed ID: 22134481
[TBL] [Abstract][Full Text] [Related]
35. Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymphoblastic Leukaemia.
Molinos-Quintana A; Aquino V; Montero I; Pérez-de Soto C; García-Lozano R; Pérez-Simón JA; Pérez-Hurtado JM
Acta Haematol; 2015; 134(2):71-5. PubMed ID: 25895602
[TBL] [Abstract][Full Text] [Related]
36. BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?
Chiaretti S; Messina M; Foà R
Cancer; 2019 Jan; 125(2):194-204. PubMed ID: 30561755
[TBL] [Abstract][Full Text] [Related]
37. Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.
Boer JM; Koenders JE; van der Holt B; Exalto C; Sanders MA; Cornelissen JJ; Valk PJ; den Boer ML; Rijneveld AW
Haematologica; 2015 Jul; 100(7):e261-4. PubMed ID: 25769542
[No Abstract] [Full Text] [Related]
38. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.
Mullighan CG; Miller CB; Radtke I; Phillips LA; Dalton J; Ma J; White D; Hughes TP; Le Beau MM; Pui CH; Relling MV; Shurtleff SA; Downing JR
Nature; 2008 May; 453(7191):110-4. PubMed ID: 18408710
[TBL] [Abstract][Full Text] [Related]
39. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction.
Atta J; Fauth F; Keyser M; Petershofen E; Weber C; Lippok G; Hoelzer D; Martin H
Bone Marrow Transplant; 2000 Jan; 25(1):97-104. PubMed ID: 10654022
[TBL] [Abstract][Full Text] [Related]
40. Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.
Grammatico S; Elia L; Peluso AL; Pedace L; Matarazzo M; Vitale A; Rago A; Pane F; Foà R; Cimino G
Leuk Res; 2009 Jul; 33(7):e73-4. PubMed ID: 19108887
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
